Galenica (GALN.S) said it has agreed to buy U.S. biopharma company Relypsa (RLYP.O) for $1.53 billion in cash to strengthen its Vifor Pharma unit.
Galenica's $32 per share offer for Relypsa shares represents a 59 percent premium to Wednesday's close.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle12
14:45 Spain raises taxes to try to meet EU deficit target13
15:41 U.N. imposes new sanctions on North Korea to slash cash from exports13
23:59 Samsung Electronics says reviewing shift to holding company structure15